Tag Archives: Death

California’s ‘Golden State Killer’ sentenced to life in prison

By Sharon Bernstein

SACRAMENTO, Calif. (Reuters) – A former California police officer who lived a double life as the “Golden State Killer” was sentenced to life in prison on Friday for a string of 1970’s and ’80s murders and rapes that were solved through the use of public genealogy websites.

A Sacramento County judge granted prosecutors’ request that Joseph James DeAngelo, 74, serve life in prison without the possibility of parole following emotional statements from victims or their family members in open court.

A frail DeAngelo showed no emotion during the nearly two-hour sentencing, held in a makeshift courtroom inside a ballroom at Sacramento State University so that victims and family members could spread out amid the coronavirus pandemic.

When given the opportunity to speak, DeAngelo slowly rose from a wheelchair, took off a mask, looked around at surviving victims and family members of those he murdered and said: “I’ve listened to all your statements. Each one of them. And I’m truly sorry to everyone out there. Thank you, your honor.”

In June, DeAngelo confessed to 13 murders and 13 rape-related charges for crimes carried out between 1975 and 1986 as part of a plea deal with prosecutors sparing him from a potential death sentence.

DeAngelo, whom a prosecutor on Friday called a bogeyman who haunted California for decades, also publicly admitted to dozens more rapes for which the statute of limitations had expired. Prosecutors said he invaded 120 homes across 11 counties during his crime spree.

The identity of the Golden State Killer remained a mystery, his crimes unsolved, for decades until DeAngelo’s arrest in Sacramento County on April 24, 2018.

Investigators tied DeAngelo to the crimes using a then-novel technique of tracing him through family DNA from commercial genealogy websites.

‘NO MERCY’

Prosecutors from counties where he carried out his crimes told Judge Michael Bowman that he deserved no mercy.

“Over four decades – that’s a long time to wait for justice,” said Diana Becton, the Contra Costa County District Attorney, where some of DeAngelo’s crimes occurred.

Bowman said that he had no power to determine what type of prison DeAngelo is sent to.

“But the survivors have spoken clearly – the defendant deserves no mercy,” he said, as those in the courtroom burst into loud applause.

(Reporting by Sharon Bernstein; Additional reporting by Dan Whitcomb and Brad Brooks; Editing by Diane Craft, Alistair Bell and Cynthia Osterman)

WHO chief hopes coronavirus pandemic will last less than two years

By Stephanie Nebehay

GENEVA (Reuters) – The World Health Organization hopes the coronavirus pandemic will be shorter than the 1918 Spanish flu and last less than two years, WHO chief Tedros Adhanom Ghebreyesus said on Friday, if the world unites and succeeds in finding a vaccine.

The WHO has always been cautious about giving estimates on how quickly the pandemic can be dealt with while there is no proven vaccine.

Tedros said the 1918 Spanish flu “took two years to stop”.

“And in our situation now with more technology, and of course with more connectiveness, the virus has a better chance of spreading, it can move fast because we are more connected now,” he told a briefing in Geneva.

“But at the same time we have also the technology to stop it and the knowledge to stop it. So we have a disadvantage of globalization, closeness, connectedness but an advantage of better technology.

“So we hope to finish this pandemic (in) less than two years.”

He urged “national unity” and “global solidarity”.

“That is really key with utilizing the available tools to the maximum and hoping that we can have additional tools like vaccine.”

More than 22.81 million people have been reported to be infected by the coronavirus globally since it was first identified in China last year and 793,382​ have died, according to a Reuters tally.

(Reporting by Stephanie Nebehay, Michael Shields and Jo Mason; Writing by Nick Macfie; Editing by Hugh Lawson)

New York City ahead of curve on COVID-19, but faces risks going into fall: experts

By Carl O’Donnell

NEW YORK (Reuters) – New York City, once an epicenter of the novel coronavirus outbreak, has managed to contain the virus as it reopens, but faces risks of an uptick in cases in the fall, public health experts told Reuters.

The city’s success comes from a mix of high rates of compliance with local and federal public health guidance and also substantial immunity among the general population, a result of the severity of the outbreak in March and April, according to public health experts based in New York City.

“There was an alignment in New York with the state government, the healthcare system and the media on what to do – namely, lock everything down,” said Mark Jarrett, chief quality officer at Northwell Health. “The lockdown didn’t please everyone but was really well accepted.”

That contrasts with other parts of the country, where political opposition to mask wearing and lockdowns is more widespread, Jarrett added.

The rate of contagion also declined more quickly because the initial outbreak left between 25% and 50% of New Yorkers with some level of immunity, said Maria Lima, associate dean for research at the City University of New York School of Medicine.

New York is at risk for an uptick in cases as schools reopen and cold weather pushes more people indoors, the experts said.

“The big challenge is schools reopening, recreating that density anew,” which had been reduced by social distancing, said Troy Tassier, a professor of economics at Fordham University who specializes in epidemiology.

After peaking in early April at a seven day average of more than 5,000 cases per day, New York City has reduced its daily case count to an average of less than 200, according to city data.

The percentage of people tested who turned out to have the virus declined from around 70% in late March to less than 1%, and confirmed deaths have declined from over 500 per day in April to the low single digits.

The United States as a whole continues to struggle to contain the virus, clocking upwards of 45,000 cases per day. Total cases have surpassed 5.5 million and more than 170,000 people have died.

(Reporting by Carl O’Donnell in New York; Editing by Daniel Wallis)

U.S. CDC reports 172,416 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Thursday said the number of deaths due to the new coronavirus had risen by 1,404 to 172,416 and reported 5,506,929 cases, an increase of 46,500 cases from its previous count.

The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 pm ET on Aug. 19 compared with its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting By Mrinalika Roy in Bengaluru; Editing by Devika Syamnath)

What you need to know about the coronavirus right now

(Reuters) – Here’s what you need to know about the coronavirus right now:

Concerns grow that kids spread virus

U.S. students are returning to school in person and online in the middle of a pandemic, and the stakes for educators and families are rising in the face of emerging research that shows children could be a risk for spreading the new coronavirus.

Several large studies have shown that the vast majority of children who contract COVID-19, the disease caused by the virus, have milder illness than adults. And early reports did not find strong evidence of children as major contributors to the deadly virus that has killed more than 780,000 people globally.

But more recent studies are starting to show how contagious infected children, even those with no symptoms, might be.

Grave situation in renewed South Korea outbreak

Novel coronavirus infections have spread nationwide from a church in the South Korean capital, raising fears that one of the world’s virus mitigation success stories might yet suffer a disastrous outbreak, a top health official said on Thursday.

“The reason we take the recent situation seriously is because this transmission, which began to spread around a specific religious facility, is appearing nationwide through certain rallies,” Vice Health Minister Kim Gang-lip told a briefing.

The positive cases from the rallies include people from nine different cities and provinces across the country. Kim did not identify those places but said 114 facilities, including the places of work of infected people, were facing risk of transmission.

Brazil sees signs spread is slowing

The spread of the coronavirus in Brazil could be about to slow, the Health Ministry said, amid reports the transmission rate has fallen below a key level and early signs of a gradual decline in the weekly totals of cases and fatalities.

The cautious optimism comes despite figures again showing a steady rise in the number of confirmed cases and death toll in the last 24 hours, cementing Brazil’s status as the world’s second biggest COVID-19 hot spot after the United States.

According to ministry data, Brazil saw a drop in the number of new confirmed COVID-19 cases to 304,684 last week from a peak of 319,653 in the week ending July 25. The weekly death toll fell to 6,755 from a peak of 7,677 in the last week of July.

Trump touts convalescent plasma as treatment

U.S. President Donald Trump on Wednesday touted the use of convalescent plasma as a treatment for COVID-19 and suggested a reported decision by regulators to put on hold an emergency authorization for its use could be politically motivated. “I’ve heard fantastic things about convalescent plasma,” Trump told a briefing.

An emergency approval by the Food and Drug Administration (FDA) for the use of blood plasma as a coronavirus treatment has been put on hold over concerns the data backing it was too weak, the New York Times reported on Wednesday. The FDA did not respond to a request for comment.

People who survive an infectious disease such as COVID-19 are left with blood plasma containing antibodies the body’s immune system created to fight off a virus. This can be transfused into newly infected patients to try to aid recovery.

China backs Wuhan park after pool party

Chinese state newspapers threw their support behind an amusement park in the central city of Wuhan on Thursday after pictures of a densely packed pool party at the park went viral overseas amid concerns about the spread of COVID-19.

Videos and photos of an electronic music festival at the Wuhan Maya Beach Water Park on July 11 raised eyebrows overseas, but reflected life returning to normal in the city where the virus causing COVID-19 was first detected, the official English-language China Daily newspaper said in a front-page story.

Another story in the Global Times, a tabloid published by the ruling Communist Party’s People’s Daily, cited Wuhan residents as saying the pool party reflected the city’s success in its virus-control efforts.

(Compiled by Linda Noakes and Karishma Singh; Editing by Mark Potter)

U.S. CDC reports 171,012 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Wednesday said the number of deaths due to the new coronavirus had risen by 1,172 to 171,012 and reported 5,460,429 cases, an increase of 39,318 cases from its previous count.

The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 pm ET on Aug. 18 versus its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Dania Nadeem in Bengaluru; Editing by Devika Syamnath)

What you need to know about the coronavirus right now

(Reuters) – Here’s what you need to know about the coronavirus right now:

Pelosi wants COVID-19 deal ‘now’

U.S. House of Representatives Speaker Nancy Pelosi said that Democrats in Congress are willing to cut their coronavirus relief bill in half to get an agreement on new legislation.

“We have to try to come to that agreement now,” Pelosi said in an online interview with Politico. “We’re willing to cut our bill in half to meet the needs right now.”

A senior House Democratic aide said Pelosi was reiterating a standing call by Democrats for the White House and Republicans to meet them “half way” on coronavirus relief.

The Democratic-led House passed legislation with more than $3 trillion in relief in May. Democrats offered this month to reduce that sum by $1 trillion, but the White House rejected it.

Mass testing in UK

Britain plans to bring in regular, population-wide testing for the novel coronavirus so it can suppress its spread and limit restrictions that have crippled one of the worst-hit countries in the world.

Health Secretary Matt Hancock said the government was carrying out trials of a range of new, faster tests that can give instant results and hoped to roll them out towards the end of the year.

Prime Minister Boris Johnson’s government has been heavily criticized for its handling of the pandemic, with critics saying it was too slow to go into lockdown and too slow to roll out testing to know how far the virus had spread.

Church outbreaks spread in South Korea

South Korea reported its highest daily rise in novel coronavirus cases since early March as outbreaks from churches around the capital spread, prompting a warning of a nationwide wave of infections.

The 297 new infections mark the sixth straight day of triple-digit increases in a country that has managed to blunt several previous outbreaks.

At least 166 of the new infections are linked to the Sarang Jeil Church, taking the number of cases from it to 623.

Some members of the church, which is run by a radical conservative preacher, are reluctant to come forward and get tested, or to self-isolate, officials have said.

Part of NZ lockdown illegal

A New Zealand court found the first nine days of a hard lockdown put in place by the government this year requiring people to isolate at home was justified, but unlawful, as an order imposing stay-at-home restrictions was not passed until April 3.

“In the end, the measures taken by the government worked to eliminate COVID-19, save lives and minimize damage to our economy,” Attorney General David Parker said after the ruling.

Prime Minister Jacinda Ardern said on Wednesday she would increase the number of defense personnel at quarantine facilities and borders to beat any spread of the virus, as five new cases in the community were reported.

A warning from the Pope

Rich countries should not hoard a coronavirus vaccine and should only give pandemic-related bailouts to companies committed to protecting the environment, helping the most needy and the “common good”, Pope Francis said on Wednesday.

“It would be sad if the rich are given priority for the COVID-19 vaccine. It would be sad if the vaccine becomes property of this or that nation, if it is not universal and for everyone,” Francis said at his weekly general audience.

The World Health Organization said on Tuesday that any nation that hoards possible vaccines while excluding others would deepen the pandemic.

“The pandemic is a crisis and one never exits from a crisis returning to the way it was before,” Francis said.

(Compiled by Linda Noakes and Karishma Singh; Editing by Robert Birsel)

Drug costs for COVID-19 patients plunge at U.S. hospitals, but may rise

By Chad Terhune

(Reuters) – Medication costs for COVID-19 patients hospitalized in the United States have dropped sharply since May, reflecting advances in treatment, shorter stays and use of cheaper generic drugs.

But costs may rise again as hospitals start to pay for Gilead Sciences Inc’s remdesivir.

Research by the health data firm IllumiCare and exclusively shared with Reuters found that hospitals spent $1,090 per COVID-19 patient on medication in July. That was down from $3,011 in May among more than 50 hospitals in 10 states that were analyzed.

Several factors drove down the number. The average length of stay for COVID-19 patients declined by nearly 30%, from 9.6 days in April to 6.8 days in July, the hospital data show. And the number of medications used dropped by 22%, from nearly 20 individual drugs in April to 15.4 drugs in July.

Pharmacists say some of the decrease in medications may stem from reduced use of ventilators, which require painkillers for sedation.

“We were throwing the kitchen sink at these patients and now hospitals are getting better at treating these infections,” said G.T. LaBorde, chief executive of IllumiCare, a Birmingham, Alabama-based firm that works with hospitals and analyzes their electronic medical records.

Remdesivir, which helped speed up patients’ recovery in a U.S. trial, won emergency-use authorization in May from U.S. regulators. Gilead donated early doses but has begun charging. It has said the price for commercially insured patients is $3,120 per treatment course and $2,340 for patients on Medicare.

Michael Ganio, senior director of pharmacy practice and quality at the American Society of Health-System Pharmacists, said many of the medications being used on COVID-19 patients are not “budget busters” and drug shortages have often been a bigger problem than cost.

But Ganio said pharmacy costs could increase significantly in the months ahead because of remdesivir.

Overall, many U.S. hospitals continue to face significant financial pressure from the pandemic as new infections remain high across much of the country, including in California, Florida and Texas. And health officials have warned that the upcoming flu season could further stress the healthcare system.

“As healthcare professionals, we are holding our breath for what fall will bring with flu season and COVID,” Ganio said.

In addition to remdesivir, hospital costs also may rise because of the increased use of tocilizumab, an anti-inflammatory drug widely used to treat arthritis. Hospital use jumped 29% among COVID-19 patients during July compared with the month earlier.

Tocilizumab costs more than $2,200 per patient, and is one of a class of drugs that includes Roche’s Actemra.

The most frequently prescribed drug for COVID-19 patients was the anticoagulant enoxaparin. It was given to 50% of inpatients last month at a cost of $322 per patient, the data show.

Another treatment recently found to reduce mortality for some COVID-19 patients, the steroid dexamethasone, costs $8.78 per patient, according to IllumiCare, and it was given to 35.1% of hospitalized COVID-19 patients reviewed in July.

Overall, IllumiCare said it looked at data from March through July at health systems in 10 states, including California, Texas and Alabama. It found more than 4,000 patients who were hospitalized and under treatment primarily for a coronavirus infection, drawing on medical billing codes for respiratory infection, sepsis and related conditions.

The firm excluded some COVID-positive patients, such as pregnant women, who were hospitalized for other reasons.

(Reporting by Chad Terhune. Editing by Peter Henderson and Gerry Doyle)

U.S. CDC reports 169,870 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday said the number of deaths due to the new coronavirus had risen by 520 to 169,870 and reported 5,422,242 cases, an increase of 40,117 cases from its previous count.

The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 pm ET on Aug. 17 compared with its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Dania Nadeem in Bengaluru; Editing by Vinay Dwivedi)

Brazil approves human trials for potential Johnson & Johnson COVID-19 vaccine

BRASILIA (Reuters) – Brazil’s health regulator Anvisa on Tuesday said it had approved human clinical trials for a potential COVID-19 vaccine developed by Johnson & Johnson’s pharmaceutical subsidiary Janssen.

Brazil is the second-worst hit country for coronavirus cases and deaths after the United States, leading many vaccine developers to seek out clinical trials here.

Brazil had registered 3.4 million cases of the disease and more than 108,000 related deaths as of Monday.

The Johnson & Johnson vaccine candidate is the fourth to be approved for human trials in Brazil, Anvisa said in its statement.

Brazil has already approved phase 3 human trials of potential vaccines developed by AstraZeneca in partnership with the University of Oxford, China’s Sinovac Biotech and Pfizer in partnership with BioNTech.

China’s Sinopharm also aims to carry out trials for a possible vaccine in Brazil in a deal with the southern state of Parana pending regulatory approval.

(Reporting by Ricardo Brito; writing by Jake Spring; editing by Alex Richardson and Jason Neely)